A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism

Journal of Hypertension

Volumn 15, Issue 7, 1997, Pages 703-714

  Inoue, Yoshihisa ^a   Nakamura, Norifumi ^a   Inagami, Tadashi ^b  

^a Green Cross Company   (South Korea)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Agonist; Angiotensin II type 1 receptor; Angiotensin receptors; Competitive antagonist; Insurmountable antagonist; Ligand binding; Ligand receptor interactions; Mutagenesis; Receptor model; Signal transduction mechanism

Indexed keywords

AMINO ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BACTERIORHODOPSIN; GUANIDINE; GUANINE NUCLEOTIDE BINDING PROTEIN;

ALPHA HELIX; BINDING SITE; CARBOXY TERMINAL SEQUENCE; HYDROGEN BOND; HYPOTHESIS; LIGAND BINDING; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; ROTATION; SIGNAL TRANSDUCTION;

EID: 0031010320     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199715070-00001     Document Type: Review

References (91)

1. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al.: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993, 45:205-251.
2. Moore GJ: Angiotensin and bradykinin receptors. Compr Med Chem 1991, 3:961-980.
3. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF: Nonpeptide angiotensin II receptor antagonists. Trend Pharmacol Sci 1991, 12:55-62.
4. Hodges JC, Hamby JM, Blankley CJ: Angiotensin II receptor binding inhibitors. Drug Future 1992, 17:575-593.
5. Steinberg MI, Wiest SA, Palkowitz AD: Nonpeptide angiotensin II receptor antagonists. Cardiovasc Drug Rev 1993, 11:312-358.
6. Chang LL, Greenlee WJ: Angiotensin II receptor antagonists: nonpeptides with equivalent high affinity for both the AT1 and AT2 subtypes. Curr Pharmaceut Design 1995, 1:407-424.
7. Wexler RR, Greenlee WJ, Irvin JD, Goldberg MR, Prendergast K, Smith RD, et al.: Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem 1996, 39:625-656.
8. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK: Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature 1995, 377:744-747.
9. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, et al.: Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995, 377:745-750.
10. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE: Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991, 315:233-236.
11. Sandberg K, Ji H, Clark AJL, Shapira H, Catt KJ: Cloning and expression of a novel angiotensin II receptor subtype. J Biol Chem 1992, 267:9455-9458.
12. Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, et al.: Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 1991, 351:230-233.
13. Bergsma DJ, Ellis C, Kumar C, Nuthulaganti P, Kersten H, Elshourbagy N, et al.: Cloning and characterization of a human angiotensin II type-1 receptor. Biochem Biophys Res Commun 1992, 183:989-995.
14. Ji H, Sandberg K, Zhang Y, Catt KJ: Molecular cloning, sequencing and functional expression of an amphibian angiotensin II receptor. Biochem Biophys Res Commun 1993, 194:756-762.
15. Bergsma DJ, Ellis C, Nuthulaganti PR, Nambi P, Scaife K, Kumar C, et al.: Isolation and expression of a novel angiotensin II receptor from Xenopus laevis heart Mol Pharmacol 1993, 44:277-284.
16. Murphy TJ, Nakamura Y, Takeuchi K, Alexander RW: A cloned angiotensin receptor isoform from the turkey adrenal gland is pharmacologically distinct from mammalian angiotensin receptors. Mol Pharmacol 1993, 44:1-7.
17. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE. Dzau VJ: Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993, 268:24539-24542.
18. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, et al.: Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 1993, 268:24543-24546.
19. Hunyady L, Balla T, Catt KJ: The ligand binding site of the angiotensin AT1 receptor. Trend Pharmacol Sci 1996, 17:135-140.
20. Griendling KK, Lassegue B, Alexander RW: Angiotensin receptors and their therapeutic implications. Ann Rev Pharmacol Toxicol 1996, 36:281-306.
21. Ji H, Leung M, Zhang Y, Catt KJ, Sandberg K: Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. J Biol Chem 1994, 269:16533-16536.
22. Noda K, Saad Y, Kinoshita A, Boyle TP, Graham RM, Husain A, et al.: Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 1995, 270:2284-2289.
23. Yamano Y, Ohyama K, Chaki S, Guo DF, Inagami T: Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site directed mutagenesis. Biochem Biophys Res Commun 1992, 187:1426-1431.
24. Yamano Y, Ohyama K, Kikyo M, Sano T, Nakagomi Y, Inoue Y, et al.: Mutagenesis and the molecular modeling of the rat angiotensin II receptor (AT1). J Biol Chem 1995, 270:14024-14030.
25. Bihoreau C, Monnot C, Davies E, Teutsch B, Bernstein KE, Corvol P. et al.: Mutation of Asp74 of the rat angiotensin II receptor confers changes in antagonist affinities and abolishes G-protein coupling. Proc Natl Acad Sci USA 1993, 90:5133-5137.
26. Marie J, Maigret B, Joseph MP, Larguier R, Nouet S, Lombard C, et al.: Tyr292 in the seventh transmembrane domain of the AT1a angiotensin II receptor is essential for its coupling to phospholipase C. J Biol Chem 1994, 269:20815-20818.
27. Schambye HT, Hjorth SA, Bergsma DJ, Sathe G, Schwartz TW: Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors. Proc Natl Acad Sci USA 1994, 91:7046-7050.
28. Schwartz TW, Gether U, Schambye HT, Hjorth SA: Molecular mechanism of action of non-peptide ligands for peptide receptors. Curr Pharm Drug 1995, 1:325-342.
29. Henderson R, Baldwin JM, Ceska TA, Zemlin F, Beckmann E, Downing KH: Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J Mol Biol 1990, 213:899-929.
30. Donnely D, Findlay JBC: Seven-helix receptors: structure and modelling. Curr Opinion Struct Biol 1994, 4:582-589.
31. Strader CD, Fong TM, Tota MB, Underwood D, Dixon RAF: Structure and function of G protein-coupled receptors. Annu Rev Biochem 1994, 63:101-132.
32. van Rhee AM, Jacobson KA: Molecular architecture of G protein-coupled receptors. Drug Develop Res 1996, 37:1-38.
33. Underwood DJ, Strader CD, Rivero R, Patchett AA, Greenlee W, Prendergast K: Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. Chem Biol 1996, 1:211-221.
34. Joseph MP, Maigret B, Bonnafous JC, Marie J, Scheraga HA: A computer modeling postulated mechanism for angiotensin II receptor activation. J Protein Chem 1995, 14:381-398.
35. Naka T: Angiotensin II receptor antagonist activities and mode of action of benzimidazole-7-carboxylic acid derivatives [in Japanese]. Nihon Rinsho 1993, 51:167-171.
36. Feng YH, Noda K, Saad Y, Liu XP, Husain A, Karnik SS: The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism. J Biol Chem 1995, 270:12846-12850.
37. Joseph MP, Maigret B, Scheraga HA: Proposals for the angiotensin II receptor-bound conformation by comparative computer modeling of All and cyclic analog. Int J Pept Protein Res 1995, 46:514-526.
38. Matsoukas JM, Agelis G, Wahhab A, Hondrelis J, Panagiotopoulos D, Yamdagni R, et al.: Differences in backbone structure between angiotensin II agonists and type 1 antagonists. J Med Chem 1995, 38:4660-4669.
39. Pierson ME, Freer RJ: Analysis of the active conformation of angiotensin II: a comparison of All and non-peptide All antagonists. Pept Res 1992, 5:102-105.
40. Nikiforovich GV, Marshall GR: Three-dimensional recognition requirements for angiotensin agonists: a novel solution for an old problem. Biochem Biophys Res Commun 1993, 195:222-228.
41. Nikiforovich GV, Kao JLF, Plucinska K, Zhang WJ, Marshall GR: Conformational analysis of two cyclic analogs of angiotensin: implications for the biologically active conformation. Biochemistry 1994, 33:3591-3598.
42. Zhang WJZ, Nikiforovich GV, Perodin J, Richard DE, Escher E, Marshall GR: Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications. J Med Chem 1996, 39:2738-2744.
43. Strange PG: The energetics of ligand binding at catecholamine receptors. Trend Pharmacol Sci 1996, 17:238-244.
44. Liao MJ, London E, Khorana JG: Regeneration of the native bacteriorhodopsin structure from two chymotryptic fragments. J Biol Chem 1983, 258:9949-9955.
45. Suwa M, Hirokawa T, Mitaku S: A continuum theory for the prediction of lateral and rotational positioning of alpha-helices in membrane proteins: bacteriorhodopsin. Proteins Struct Funct Genet 1995, 22:363-377.
46. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, et al.: A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 1996, 271:16384-16392.
47. Ng GYK, O'Dowd BF, Lee SP, Chung HT, Brann MR, Seeman P, et al.: Dopamine D2 receptor dimers and receptor-blocking peptides. Biochem Biophys Res Commun 1996, 227:200-204.
48. Monnot C, Bihoreau C, Conchon S, Curnow KM, Corvol P, Ctauser E: Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling. J Biol Chem 1996, 271:1507-1513.
49. Hibert MF, Trumpp-Kallmeyer S, Bruinvels A, Hoflack J: Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol Pharmacol 1991, 40:8-15.
50. Nishio M, Umezawa Y, Hirota M, Takeuchi Y: The CH/π interaction: significance in molecular recognition. Tetrahedron 1995, 32: 8665-8701.
51. Suzuki S, Green PG, Bumgamer RE, Dasgupta S, Goddard WA III, Blake GA: Benzene forms hydrogen bonds with water. Science 1992, 257:942-945.
52. Caldwell JW, Kollman PA: Cation-π interactions: nonadditive effects are critical in their accurate representation. J Am Chem Soc 1995, 117:4177-4178.
53. Dougherty DA: Cation-π interactions in chemistry and biology: a new view of benzene, Phe, Tyr and Trp. Science 1996, 271:163-168.
54. Fong TM, Cascieri MA, Yu H, Bansal A, Swain C, Strader CD: Amino-aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345. Nature 1993, 362:350-353.
55. Swain CJ, Seward EM, Cascieri MA, Fong TM, Herbert R, Maclntyre DE, et al.: Identification of a series of 3-(benzyloxy)-1-azabicyclo[2.2.2]-octane human NK1 antagonists. J Med Chem 1995, 38:4793-4805.
56. Waksman G, Kominos D, Robertson SC, Pant N, Baltimore D, Birge RB, et al.: Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides. Nature 1992, 358:646-653.
57. Mitchell JBO, Nandi CL, McDonald IK, Thornton JM, Price SL: Amino/aromatic interactions in proteins: is the evidence stacked against hydrogen bonding? J Mol Biol 1994, 239:315-331.
58. Flocco MM, Mowbray SL: Planar stacking interactions of arginine and aromatic side-chains in proteins. J Mol Biol 1994, 235:709-717.
59. Hunter CA, Singh J, Thornton JM: Pi-pi interactions: the geometry and energetics of phenylalanine-phenylalanine interactions in proteins. J Mol Biol 1994, 218:837-846.
60. Noda K, Saad Y, Karnik SS: Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. J Biol Chem 1995, 270:28511-28514.
61. Cheetham JC, Artymiuk PJ, Phillips DC: Refinement of an enzyme complex with inhibitor bound at partial occupancy. Hen egg-white lysozime and tri-N-acetylchitotoriose at 1.75Å resolution. J Mol Biol 1992, 224:613-628.
62. Yamano Y, Ohyama K, Kikyo Y, Suzuki K, Sano T, Nakagomi Y, et al.: Mutagenesis and the molecular modeling of the rat angiotensin II receptor (AT1). Part 2. J Biol Chem 1996, submitted.
63. Schiffer M, Chang CH, Stevens FJ: The function of tryptophan residues in membrane proteins. Protein Eng 1992, 5:213-214.
64. Gether U, Lin S, Kobilka BK: Fluorescent labeling of purified beta2 adrenergic receptor. J Biol Chem 1995, 270:28268-28275.
65. Ohyama K, Yamano Y, Sano T, Nakagomi Y, Hamakubo T, Morishima T, et al.: Disulfide bridges in extracellular domains of angiotensin II receptor type 1a. Regulatory Pept 1995, 57:141-147.
66. Panek RL, Lu GH, Overhiser RW, Major TC, Hodges JC, Taylor DG: Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J Pharmacol Exp Ther 1995, 273:753-761.
67. Unwin N: Acetylcholine receptor channel imaged in the open state. Nature 1995, 373:37-43.
68. Donetli A, Cereda E, Bellora E, Gallazzi A, Bazzano C, Vanoni P, et al.: (Imidazolylphenyl)formamidines. A structurally novel class of potent histamine H2 receptor antagonists. J Med Chem 1984, 27:380-386.
69. Birdsall NJM: Cloning and structure-function of the H2 histamine receptor. Trends Pharmacol Sci 1991, 12:9-10.
70. Yamashita M, Fukui H, Sugama K, Horio Y, Ito S, Mizuguchi H, et al.: Expression cloning of a cDNA encoding the bovine histamine H1 receptor. Proc Natl Acad Sci USA 1991, 88:11515-11519.
71. Luo X, Zhang D, Weinstein H: Ligand-induced domain motion in the activation mechanism of a G-protein-coupled receptor. Protein Eng 1994, 7:1441-1448.
72. Hunyady L, Bor M, Baukal AJ, Balla T, Catt KJ: A conserved NPLLY sequence contributes to agonist binding and signal transduction but is not an internalization signal for the type 1 angiotensin II receptor. J Biol Chem 1995, 270:16602-16609 .
73. Schwartz TW, Rosenkilde MM: Is there a 'lock' for all agonist 'keys' in 7TM receptors? Trends Pharmacol Sci 1996, 17:213-216.
74. Roche PJ, Eddie LW, Gofglan JP: Characterization of a mutant type-1 angiotensin II receptor. Kidney Int 1994, 46:1580-1582.
75. Nanevicz T, Wang L, Chen M, Ishii M, Coughlin SR: Thrombin receptor activating mutations. J Biol Chem 1996, 271:702-706.
76. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J: Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta-1-adrenoceptor with positive chronotropic effect. Circulation 1994, 89:2760-2767.
77. Fu MLX, Herlitz H, Wallukat G, Hilme E, Hedner T, Hoebeke J, et al.: Functional autoimmune epitope on alpha-1-adrenergic receptors in patients with malignant hypertension. Lancet 1994, 344:1660-1663.
78. Alla SA, Quitterer U, Grigoriev S, Maidhof A, Haasemann M, Jarnagin K, et al.: Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies. J Biol Chem 1996, 271:1748-1755.
79. Pradier L, Menager J, Guern JL, Bock MD, Heuillet E, Fardin V, et al.: Septide. An agonist for the NK1 receptor acting as a site distinct from substance P. Mol Pharmacol 1994, 45:287-293.
80. Kenakin T: Agonist-receptor efficacy II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 1995, 16:232-238.
81. Capponi AM, Catt KJ: Angiotensin II receptors in adrenal cortex and uterus. J Biol Chem 1979, 254:5120-5127.
82. Tota MR, Strader CD: Characterization of the binding domain of the beta-adrenergic receptor with the fluorescent antagonist carazolol. J Biol Chem 1990, 265:16891-16897.
83. Li YM, Marnerakis M, Stimson ER, Maggio JE: Mapping peptide-binding domains of the substance P (NK-1) receptor from P388D1 cells with photolabile agonists. J Biol Chem 1995, 270:1213-1220.
84. Kyle DJ: Structure-based drug design: progress toward the discovery of the elusive bradykinin receptor antagonists. Curr Pharmaceut Design 1995, 1:233-254.
85. Perlman S, Schambye HT, Rivero RA, Greenlee WJ, Hjorth SA, Schwartz TW: Non-peptide angiotensin agonist. J Biol Chem 1995, 270:1493-1496.
86. Schambye HT, van Wijk B, Hjorth SA, Wienen W, Entzeroth M, Bergsma DJ, et al.: Mutations in transmembrane segment VII of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists. Br J Pharmacol 1994, 113:331-333.
87. Ji H, Zheng W, Zhang Y, Catt KJ, Sandberg K: Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor. Proc Natl Acad Sci USA 1995, 92:9240-9244.
88. Suryanarayana S, Zastrow MV, Kobilka BK: Identification of intramolecular interactions in adrenergic receptors. J Biol Chem 1992, 267:21991-21994.
89. Schambye HT, Hjorth SA, Weinstock J, Schwartz TW: Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor. Mol Pharmacol 1995, 47:425-431.
90. Groblewski T, Maigret B, Nouet S, Larguier R, Lombard C, Bonnafous JC, et al.: Amino acids of the third transmembrane domain of the AT1a angiotensin II receptor are involved in the differential recognition of peptide and nonpeptide ligands. Biochem Biophys Res Commun 1995, 209:153-160.
91. Hjorth SA, Schambye HT, Greenlee WJ, Schwartz TW: Identification of peptide binding residues in the extracellular domains of the AT1 receptor. J Biol Chem 1994, 269:30953-30959.